Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda

Carole D. Mitnick, Carly A. Rodriguez, Marita L. Hatton, Grania Brigden, Frank Cobelens, Martin P. Grobusch, Robert Horsburgh, Christoph Lange, Christian Lienhardt, Eyal - Oren, Laura J. Podewils, Barbara Seaworth, Susan Den Van Hof, Charles L. Daley, Agnes C. Gebhard, Fraser Wares

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Introduction There are numerous challenges in delivering appropriate treatment for multidrug-resistant tuberculosis (MDR-TB) and the evidence base to guide those practices remains limited. We present the third updated Research Agenda for the programmatic management of drugresistant TB (PMDT), assembled through a literature review and survey. Methods Publications citing the 2008 research agenda and normative documents were reviewed for evidence gaps. Gaps were formulated into questions and grouped as in the 2008 research agenda: Laboratory Support, Treatment Strategy, Programmatically Relevant Research, Epidemiology, and Management of Contacts. A survey was distributed through snowball sampling to identify research priorities. Respondent priority rankings were scored and summarized by mean. Sensitivity analyses explored weighting and handling of missing rankings. Results Thirty normative documents and publications were reviewed for stated research needs; these were collapsed into 56 research questions across 5 categories. Of more than 500 survey recipients, 133 ranked priorities within at least one category. Priorities within categories included new diagnostics and their effect on improving treatment outcomes, improved diagnosis of paucibacillary and extra pulmonary TB, and development of shorter, effective regimens. Interruption of nosocomial transmission and treatment for latent TB infection in contacts of known MDR-TB patients were also top priorities in their respective categories. Results were internally consistent and robust. Discussion Priorities retained from the 2008 research agenda include shorter MDR-TB regimens and averting transmission. Limitations of recent advances were implied in the continued quest for: shorter regimens containing new drugs, rapid diagnostics that improve treatment outcomes, and improved methods of estimating burden without representative data. Conclusion There is continuity around the priorities for research in PMDT. Coordinated efforts to address questions regarding shorter treatment regimens, knowledge of disease burden without representative data, and treatment for LTBI in contacts of known DR-TB patients are essential to stem the epidemic of TB, including DR-TB.This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Original languageEnglish (US)
Article numbere0155968
JournalPLoS One
Volume11
Issue number5
DOIs
StatePublished - May 1 2016

Fingerprint

Multidrug-Resistant Tuberculosis
tuberculosis
drugs
Research
Pharmaceutical Preparations
Publications
research management
Epidemiology
burden of disease
prioritization
Therapeutics
new drugs
Research laboratories
Public Sector
Anniversaries and Special Events
epidemiology
lungs
Sampling
stems
Lung

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Mitnick, C. D., Rodriguez, C. A., Hatton, M. L., Brigden, G., Cobelens, F., Grobusch, M. P., ... Wares, F. (2016). Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda. PLoS One, 11(5), [e0155968]. https://doi.org/10.1371/journal.pone.0155968

Programmatic Management of Drug-Resistant Tuberculosis : An Updated Research Agenda. / Mitnick, Carole D.; Rodriguez, Carly A.; Hatton, Marita L.; Brigden, Grania; Cobelens, Frank; Grobusch, Martin P.; Horsburgh, Robert; Lange, Christoph; Lienhardt, Christian; Oren, Eyal -; Podewils, Laura J.; Seaworth, Barbara; Van Hof, Susan Den; Daley, Charles L.; Gebhard, Agnes C.; Wares, Fraser.

In: PLoS One, Vol. 11, No. 5, e0155968, 01.05.2016.

Research output: Contribution to journalArticle

Mitnick, CD, Rodriguez, CA, Hatton, ML, Brigden, G, Cobelens, F, Grobusch, MP, Horsburgh, R, Lange, C, Lienhardt, C, Oren, E, Podewils, LJ, Seaworth, B, Van Hof, SD, Daley, CL, Gebhard, AC & Wares, F 2016, 'Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda', PLoS One, vol. 11, no. 5, e0155968. https://doi.org/10.1371/journal.pone.0155968
Mitnick CD, Rodriguez CA, Hatton ML, Brigden G, Cobelens F, Grobusch MP et al. Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda. PLoS One. 2016 May 1;11(5). e0155968. https://doi.org/10.1371/journal.pone.0155968
Mitnick, Carole D. ; Rodriguez, Carly A. ; Hatton, Marita L. ; Brigden, Grania ; Cobelens, Frank ; Grobusch, Martin P. ; Horsburgh, Robert ; Lange, Christoph ; Lienhardt, Christian ; Oren, Eyal - ; Podewils, Laura J. ; Seaworth, Barbara ; Van Hof, Susan Den ; Daley, Charles L. ; Gebhard, Agnes C. ; Wares, Fraser. / Programmatic Management of Drug-Resistant Tuberculosis : An Updated Research Agenda. In: PLoS One. 2016 ; Vol. 11, No. 5.
@article{d60ec0d026f24fccad0bd5a021a08ade,
title = "Programmatic Management of Drug-Resistant Tuberculosis: An Updated Research Agenda",
abstract = "Introduction There are numerous challenges in delivering appropriate treatment for multidrug-resistant tuberculosis (MDR-TB) and the evidence base to guide those practices remains limited. We present the third updated Research Agenda for the programmatic management of drugresistant TB (PMDT), assembled through a literature review and survey. Methods Publications citing the 2008 research agenda and normative documents were reviewed for evidence gaps. Gaps were formulated into questions and grouped as in the 2008 research agenda: Laboratory Support, Treatment Strategy, Programmatically Relevant Research, Epidemiology, and Management of Contacts. A survey was distributed through snowball sampling to identify research priorities. Respondent priority rankings were scored and summarized by mean. Sensitivity analyses explored weighting and handling of missing rankings. Results Thirty normative documents and publications were reviewed for stated research needs; these were collapsed into 56 research questions across 5 categories. Of more than 500 survey recipients, 133 ranked priorities within at least one category. Priorities within categories included new diagnostics and their effect on improving treatment outcomes, improved diagnosis of paucibacillary and extra pulmonary TB, and development of shorter, effective regimens. Interruption of nosocomial transmission and treatment for latent TB infection in contacts of known MDR-TB patients were also top priorities in their respective categories. Results were internally consistent and robust. Discussion Priorities retained from the 2008 research agenda include shorter MDR-TB regimens and averting transmission. Limitations of recent advances were implied in the continued quest for: shorter regimens containing new drugs, rapid diagnostics that improve treatment outcomes, and improved methods of estimating burden without representative data. Conclusion There is continuity around the priorities for research in PMDT. Coordinated efforts to address questions regarding shorter treatment regimens, knowledge of disease burden without representative data, and treatment for LTBI in contacts of known DR-TB patients are essential to stem the epidemic of TB, including DR-TB.This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.",
author = "Mitnick, {Carole D.} and Rodriguez, {Carly A.} and Hatton, {Marita L.} and Grania Brigden and Frank Cobelens and Grobusch, {Martin P.} and Robert Horsburgh and Christoph Lange and Christian Lienhardt and Oren, {Eyal -} and Podewils, {Laura J.} and Barbara Seaworth and {Van Hof}, {Susan Den} and Daley, {Charles L.} and Gebhard, {Agnes C.} and Fraser Wares",
year = "2016",
month = "5",
day = "1",
doi = "10.1371/journal.pone.0155968",
language = "English (US)",
volume = "11",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - Programmatic Management of Drug-Resistant Tuberculosis

T2 - An Updated Research Agenda

AU - Mitnick, Carole D.

AU - Rodriguez, Carly A.

AU - Hatton, Marita L.

AU - Brigden, Grania

AU - Cobelens, Frank

AU - Grobusch, Martin P.

AU - Horsburgh, Robert

AU - Lange, Christoph

AU - Lienhardt, Christian

AU - Oren, Eyal -

AU - Podewils, Laura J.

AU - Seaworth, Barbara

AU - Van Hof, Susan Den

AU - Daley, Charles L.

AU - Gebhard, Agnes C.

AU - Wares, Fraser

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Introduction There are numerous challenges in delivering appropriate treatment for multidrug-resistant tuberculosis (MDR-TB) and the evidence base to guide those practices remains limited. We present the third updated Research Agenda for the programmatic management of drugresistant TB (PMDT), assembled through a literature review and survey. Methods Publications citing the 2008 research agenda and normative documents were reviewed for evidence gaps. Gaps were formulated into questions and grouped as in the 2008 research agenda: Laboratory Support, Treatment Strategy, Programmatically Relevant Research, Epidemiology, and Management of Contacts. A survey was distributed through snowball sampling to identify research priorities. Respondent priority rankings were scored and summarized by mean. Sensitivity analyses explored weighting and handling of missing rankings. Results Thirty normative documents and publications were reviewed for stated research needs; these were collapsed into 56 research questions across 5 categories. Of more than 500 survey recipients, 133 ranked priorities within at least one category. Priorities within categories included new diagnostics and their effect on improving treatment outcomes, improved diagnosis of paucibacillary and extra pulmonary TB, and development of shorter, effective regimens. Interruption of nosocomial transmission and treatment for latent TB infection in contacts of known MDR-TB patients were also top priorities in their respective categories. Results were internally consistent and robust. Discussion Priorities retained from the 2008 research agenda include shorter MDR-TB regimens and averting transmission. Limitations of recent advances were implied in the continued quest for: shorter regimens containing new drugs, rapid diagnostics that improve treatment outcomes, and improved methods of estimating burden without representative data. Conclusion There is continuity around the priorities for research in PMDT. Coordinated efforts to address questions regarding shorter treatment regimens, knowledge of disease burden without representative data, and treatment for LTBI in contacts of known DR-TB patients are essential to stem the epidemic of TB, including DR-TB.This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

AB - Introduction There are numerous challenges in delivering appropriate treatment for multidrug-resistant tuberculosis (MDR-TB) and the evidence base to guide those practices remains limited. We present the third updated Research Agenda for the programmatic management of drugresistant TB (PMDT), assembled through a literature review and survey. Methods Publications citing the 2008 research agenda and normative documents were reviewed for evidence gaps. Gaps were formulated into questions and grouped as in the 2008 research agenda: Laboratory Support, Treatment Strategy, Programmatically Relevant Research, Epidemiology, and Management of Contacts. A survey was distributed through snowball sampling to identify research priorities. Respondent priority rankings were scored and summarized by mean. Sensitivity analyses explored weighting and handling of missing rankings. Results Thirty normative documents and publications were reviewed for stated research needs; these were collapsed into 56 research questions across 5 categories. Of more than 500 survey recipients, 133 ranked priorities within at least one category. Priorities within categories included new diagnostics and their effect on improving treatment outcomes, improved diagnosis of paucibacillary and extra pulmonary TB, and development of shorter, effective regimens. Interruption of nosocomial transmission and treatment for latent TB infection in contacts of known MDR-TB patients were also top priorities in their respective categories. Results were internally consistent and robust. Discussion Priorities retained from the 2008 research agenda include shorter MDR-TB regimens and averting transmission. Limitations of recent advances were implied in the continued quest for: shorter regimens containing new drugs, rapid diagnostics that improve treatment outcomes, and improved methods of estimating burden without representative data. Conclusion There is continuity around the priorities for research in PMDT. Coordinated efforts to address questions regarding shorter treatment regimens, knowledge of disease burden without representative data, and treatment for LTBI in contacts of known DR-TB patients are essential to stem the epidemic of TB, including DR-TB.This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

UR - http://www.scopus.com/inward/record.url?scp=84971237998&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971237998&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0155968

DO - 10.1371/journal.pone.0155968

M3 - Article

C2 - 27223622

AN - SCOPUS:84971237998

VL - 11

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e0155968

ER -